P3 Health Partners Inc.(PIII)

Medical - Care Facilities · Henderson, NV

$5.91-0.26 (-4.21%)

Delayed quote: Oct 6, 2026, 12:40 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:44:19.759Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:44:19.759Z.

Quote observation: 2026-10-06T16:40:24.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 19,361,166
Total debt · period ending 2026-06-30: 130,271,000
Cash · period ending 2026-06-30: 21,272,000
TTM operating EBITDA · period ending 2026-06-30: -64,480,000

FMP input reference: ac2c7a41ad5640622b079511a65f3d79aa9aa97fd30809e3a9f0c7038551df0a

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PIII EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

PIII Competitors' EV/EBITDA Ratio

PIII

P3 Health Partners Inc.

Current

Market Cap

$19.36M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEUP

Neuphoria Therapeutics Inc.

vs PIII

Market Cap

$18.65M

EV/EBITDA Ratio

N/A

TTM Avg

466.09x

3Y Avg

466.09x

5Y Avg

466.09x

ESLA

Estrella Immunopharma, Inc.

vs PIII

Market Cap

$19.55M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NXTC

NextCure, Inc.

vs PIII

Market Cap

$18.95M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COSM

Cosmos Health Inc.

vs PIII

Market Cap

$17.65M

EV/EBITDA Ratio

N/A

TTM Avg

47.55x

3Y Avg

64.91x

5Y Avg

64.91x

ACTU

Actuate Therapeutics Inc

vs PIII

Market Cap

$19.77M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PAVM

PAVmed Inc.

vs PIII

Market Cap

$17.27M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LPCN

Lipocine Inc.

vs PIII

Market Cap

$17.30M

EV/EBITDA Ratio

N/A

TTM Avg

19.19x

3Y Avg

19.19x

5Y Avg

19.19x

MRKR

Marker Therapeutics, Inc.

vs PIII

Market Cap

$17.01M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PTN

Palatin Technologies, Inc.

vs PIII

Market Cap

$16.76M

EV/EBITDA Ratio

N/A

TTM Avg

197.20x

3Y Avg

1380.98x

5Y Avg

1380.98x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
P3 Health Partners Inc. (PIII)	$19.36M	N/A	N/A	N/A	N/A
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.65M	N/A	466.09x	466.09x	466.09x
Estrella Immunopharma, Inc. (ESLA)vs ›	$19.55M	N/A	N/A	N/A	N/A
NextCure, Inc. (NXTC)vs ›	$18.95M	N/A	N/A	N/A	N/A
Cosmos Health Inc. (COSM)vs ›	$17.65M	N/A	47.55x	64.91x	64.91x
Actuate Therapeutics Inc (ACTU)vs ›	$19.77M	N/A	N/A	N/A	N/A
PAVmed Inc. (PAVM)vs ›	$17.27M	N/A	N/A	N/A	N/A
Lipocine Inc. (LPCN)vs ›	$17.30M	N/A	19.19x	19.19x	19.19x
Marker Therapeutics, Inc. (MRKR)vs ›	$17.01M	N/A	N/A	N/A	N/A
Palatin Technologies, Inc. (PTN)vs ›	$16.76M	N/A	197.20x	1380.98x	1380.98x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics